March 2016

MannKind: Path to Afrezza Survival Involves Lower Prices to Woo Payers

March 15, 2016

Evidence-Based Diabetes Management

Did MannKind misjudge consumer demand, or are barriers from payers to blame for Afrezza's woes? A feature outlining the misfortunes and future plans for the only inhaled insulin on the market.

When Quality Fails Patients: Finding the Best in Diabetes Care

March 16, 2016

Evidence-Based Diabetes Management

Authors from the Mayo Clinic discuss situational goals in diabetes care, because quality targets enforced too strictly may harm patients who are working hard to manage their disease.

Measuring the Quality of Diabetes Care

March 16, 2016

Evidence-Based Diabetes Management

An introduction to the Joslin Clinical Analytic Tool, a new diabetes measure developed to adjust for the variety in patient mix and better inform clinicians which interventions will work best.

The Role of the Clinical Pharmacist in Achieving Clinical and Quality Outcomes in Diabetes Management

March 18, 2016

Evidence-Based Diabetes Management

Medication therapy management is a key component of ensuring good outcomes in diabetes care. The clinical pharmacist can play a key role in ensuring good transitions of care, avoiding problems of polypharmacy, addressing financial issues, and providing patient education.

Is Soda the New Tobacco? An Expert, and New CDC Data, Say Yes

March 18, 2016

Evidence-Based Diabetes Management

In Soda Politics, Marion Nestle, PhD, traces the history of the giant soda companies in the United States, and how they have copied the tactics of Big Tobacco to get children "drinking sugar," with resulting rates of diabetes and obesity. Other groups are joining Nestle in criticizing the export of heavy soda marketing to the developing world.